Cancer-on-a-chip systems at the frontier of nanomedicine

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Nanomedicine enhances drug delivery and efficacy but faces slow clinical translation.
• Conventional cell and animal models have limitations in replicating human tumor microenvironments.
• Organ-on-a-chip technology has evolved significantly for disease modeling.

Purpose of the Study:

• To discuss the utility of cancer-on-a-chip platforms for evaluating nanomedicine.
• To highlight the limitations of current preclinical models for nanomedicine assessment.
• To explore the potential of advanced in vitro models in oncology research.

Main Methods:

• Review of nanomedicine principles and challenges.
• Historical overview of organ-on-a-chip development.
• Analysis of cancer-on-a-chip platforms for nanomedicine efficacy testing.
• Discussion of human tumor microenvironment replication.

Main Results:

• Cancer-on-a-chip platforms closely mimic human tumor pathophysiology.
• These platforms provide a more accurate preclinical evaluation of nanomedicine compared to traditional models.
• The technology shows potential for accelerating the development of novel cancer therapies.

Conclusions:

• Cancer-on-a-chip platforms represent a significant advancement for preclinical nanomedicine evaluation.
• They offer a more predictive model for assessing drug efficacy and tumor response.
• Future development of these platforms is crucial for overcoming barriers in nanomedicine translation.